Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 43Colorectal Neoplasms 8Uveal Melanoma 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Stomach Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 3Carcinoma, Merkel Cell 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pancreatic Neoplasms 2Glioblastoma 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parotid Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1

Interventions

HhAntag691 25Imiquimod 12Biopsy 12sonidegib 11Aminolevulinic Acid 9cemiplimab 8Photochemotherapy 8Nivolumab 8methyl 5-aminolevulinate 7Mohs Surgery 71-phenyl-3,3-dimethyltriazene 7Tomography, Optical Coherence 6Surgical Procedures, Operative 6Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Microscopy, Confocal 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Standard of Care 3Niacinamide 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × Bevacizumab × Dermatologic × Clear all
NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Genentech, Inc.

Phase 2 Completed
19 enrolled 10 charts
DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡